For smaller drug discovery and specialty pharmaceutical companies, speed matters. A promising
molecule or formulation can lose momentum if the company cannot secure the right API,
intermediate, formulation support, or manufacturing pathway at the right time.
Many early-stage companies do not have large procurement teams, global supplier networks, or
in-house manufacturing infrastructure. They may know the product they want to develop, but still
need support with API access, dosage pathway, formulation review, documentation, scale-up,
batch requirements, and commercial planning.
This is where CDMO support becomes important.
A good CDMO pathway can help bridge the gap between discovery and commercialization.
Depending on the project, support may include custom synthesis, formulation development,
route development, non-GMP manufacturing, GMP manufacturing, scale-up coordination,
technology transfer, batch testing, and documentation review.
For smaller companies, the key is not only finding a manufacturer. It is finding a practical path
that matches the stage of the program. A preclinical project, clinical program, and commercial
launch all require different levels of manufacturing discipline, documentation, quality review, and
regulatory planning.
Ventalys supports emerging pharmaceutical companies by helping review API and intermediate
needs, CDMO requirements, dosage format, documentation expectations, and commercial supply
options. Our goal is to help promising programs move forward with better clarity and fewer
supply-chain delays.
